eGuidelines.co.uk
51,537 registered users
|


Evidence summaries: unlicensed/off-label medicines summarise the best available evidence for selected unlicensed and off-label medicines.

Unlicensed and off-label medicines have a valuable role in the care of certain patients when there are no suitable licensed medicines available which meet their needs. However, information for healthcare professionals and patients to decide whether these medicines are safe and effective, and when they are most likely to yield good patient outcomes, can be difficult to find. It is estimated that around 1000 specific requests for off-label drug use are made to NHS commissioners in England every year.

The summaries are the first nationally-available source of information for healthcare professionals and patients. They allow evidence-based prioritisation, treatment and funding decisions to be made where there are no clinically-appropriate licensed alternatives.

The strengths and weaknesses of the relevant evidence are critically reviewed, but the summaries do not constitute formal NICE guidance.

Further information about Evidence summaries: unlicensed/off-label medicines can be found on the NICE website.

Next >    >>

Date Title
Oct 2013 Bile acid malabsorption: colesevelam
Oct 2013 Postural hypotension in adults: fludrocortisone
Oct 2013 Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatn for first-line treatment
Sep 2013 Schizophrenia: omega-3 fatty acid supplements
Jul 2013 Promoting tolerance of enteral feeds in children and young people: domperidone
Jul 2013 Multidrug resistant urinary tract infections: fosfomycin trometamol
Jul 2013 Hyperhidrosis: oral glycopyrronium bromide
Jul 2013 Hypersalivation: oral glycopyrronium bromide
Jun 2013 Chronic anal fissure: botulinum toxin type A injection
Jun 2013 Gastroparesis in adults: oral erythromycin

Next >    >>